Merck's Fosamax Plus D To Be Priced On Par With Predecessor
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck's Fosamax Plus D adds weekly dose of vitamin D to the once-weekly osteoporosis agent. Plus D will reach the market around the same time as Roche/GlaxoSmithKline's once-monthly Boniva.
You may also be interested in...
P&G/Sanofi Combine Actonel With Calcium In 28-Day Regimen
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.
P&G/Sanofi Combine Actonel With Calcium In 28-Day Regimen
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.
Roche/GSK Boniva Once-Monthly To Be Launched In April
The companies are planning "substantial" DTC ad campaigns, Roche says. FDA approves supplemental NDA for once-monthly ibandronate for treatment of osteoporosis in postmenopausal women. Boniva will be priced competitively to the currently marketed bisphosphonates, Roche says.